Mehdi El Glaoui

About Mehdi El Glaoui

Mehdi El Glaoui is an experienced business executive and board director, currently serving on the Board of Directors of Theraclion, a French medtech company focused on echotherapy and high-intensity focused ultrasound solutions. His role at Theraclion is primarily strategic and governance-oriented, supporting a listed company that develops non-invasive treatments, especially in venous care and other therapeutic ultrasound applications. He joined Theraclion’s board in 2021 following an investment in the company, and his appointment was later ratified by shareholders. Mehdi El Glaoui holds a Doctor of Pharmacy degree from the Faculty of Pharmacy of Paris V, giving him a strong scientific foundation for a career in healthcare and life sciences. He built his professional track record in the pharmaceutical industry, where he served as Chairman and Chief Executive Officer of Cassenne Laboratories and later of Wyeth Laboratories. These leadership roles gave him extensive experience in corporate management, commercial development, and operating within highly regulated healthcare environments. He later became Chairman of Louis Dreyfus Commodities in Geneva and subsequently a board member, demonstrating his ability to contribute at senior level in large international organizations. In 2011, he founded Majorelle International, a company specialized in pharmaceutical development, reinforcing his profile as both an operator and an investor. This blend of scientific training, executive leadership, and entrepreneurial activity is particularly relevant for Theraclion, a company seeking to scale an innovative medical technology platform. The company described him as bringing expertise and vision to support its transition from an innovative medtech model toward a more disruptive healthtech growth story. At Theraclion, he contributes strategic judgment, sector expertise, and a long-term perspective on value creation, innovation, and international expansion.